Cure Alzheimer's Fund

Our mission is to fund research with the highest probability of preventing, slowing or reversing Alzheimer's Disease through venture based philanthropy. All organizational expenses are paid for by the Founders and Board, allowing all other contributions to be applied directly to Alzheimer's Disease research.
Jan 4, 2017

Cure Alzheimer's Fund and Rotary Co-Fund Research

Cure Alzheimer’s Fund and Rotary joined forces this fall to fund research into why women are more likely to get Alzheimer’s disease than men. The two organizations granted a total of $375,000 to the lab of Rudy Tanzi, Ph.D., at Massachusetts General Hospital. Tanzi, who serves as the Research Consortium chair for Cure Alzheimer’s Fund, will analyze existing databases of Alzheimer’s family genomes to identify gene variants that impact risk differently for women than for men.

Women and Alzheimer’s

Of the 5.4 million Americans living with Alzheimer’s disease, nearly two-thirds are women. While researchers and clinicians have observed this phenomenon for some time, the reasons why incidence among women is greater are unknown, and little research has been done to determine possible genetic underpinnings. Women do have a longer expected lifespan than men, but this difference alone does not explain the observed imbalance in incidence of the disease. At age 65, women face twice the lifetime risk of developing Alzheimer’s than men. At 75, their risk is nearly threefold.

Women also exhibit faster cognitive decline than do men. In one study, women with mild cognitive impairment, a diagnosis that often precedes Alzheimer’s, increased their rate of cognitive errors faster than did their male counterparts when tested over several years. This seems to show that not only are women at higher risk of Alzheimer’s, but they also are affected by the disease in different ways.

Rotary

While this is the first time Rotary and Cure Alzheimer’s Fund have co-funded a research grant, the two organizations have ties going back several years. The initiative started with a chance meeting between Jeff Morby, co-chairman and co-founder of Cure Alzheimer’s Fund, and Dick Pratt, a member of the Martha’s Vineyard Rotary Club. Members of that club joined others in New England and ultimately from around the world to champion more attention and resources to combat the global scourge of Alzheimer’s disease.

In 2013, Martha’s Vineyard Rotary officially partnered with Cure Alzheimer’s Fund to create the Alzheimer’s Disease Rotary Action Group (adrag.org). In addition to funding more research like Tanzi’s, the group hopes to promote awareness of Alzheimer’s and its impact by partnering with local communities served by Rotary around the world. The initiative to fund Tanzi’s work was a joint effort between the Martha’s Vineyard Rotary Club and the Toronto Rotary Club. Rotary funding for the project was provided by The Rotary Foundation, a nonprofit charity.

The project

Tanzi’s study about women and Alzheimer’s stood out to both Rotary and CureAlz as an excellent co-funding opportunity. The percentage of women in Rotary is growing rapidly, as are members from the Indian subcontinent, a population dealing with increased rates of Alzheimer’s. Many current Rotary members have a parent, spouse or other loved one suffering from the disease.

Tanzi will be working with three databases of genetic samples from Alzheimer’s families: one from the National Institute of Mental Health (NIMH), one from the National Institute on Aging (NIA) and one from the National Cell Repository for Alzheimer’s Disease (NCRAD). This wealth of genetic data already has been screened by Tanzi and others for genes and variants that appear statistically associated with risk for Alzheimer’s. However, no one has attempted to mine the databases for risk factors specific to men or women.

“Studying sex-based differences is a harder problem, computationally speaking,” Tanzi explained. “On Chromosome 23—XX in women, XY in men—you sometimes have multiple copies of a gene, or silenced genes. Historically, these complications have pushed geneticists doing genome-wide association studies to omit the sex chromosome, or avoid breaking out men and women in their results.”

Tanzi will work with Christoph Lange, Ph.D., at the Harvard School of Public Health, to write new high-powered algorithms for sex differentiation risk analysis. The grant from Rotary and Cure Alzheimer’s Fund will allow them to tackle this difficult problem that many scientists have long avoided.

The potential reward for doing such work is great. “This is important for the treatment of all patients—not only women,” Morby said. Identifying a gene that seems to be protective in men, for instance, might point to a therapy that would benefit both sexes. One specific goal is to gain a better understanding of the APOE gene; while having the APOE4 variant of this gene increases risk for any carrier, women are at significantly higher risk as carriers of the gene than men are. More broadly, the study will provide insight into the mechanisms behind Alzheimer’s pathology and expand our understanding of what goes wrong in the disease.

More studies

Cure Alzheimer’s Fund plans to support further studies into sex-based differences in Alzheimer’s disease. Murali Doraiswamy, M.D., of Duke University, currently is being funded for a study looking at trends in cognitive, biomarker and genetic data that may indicate why women are at greater risk. Doraiswamy will perform second- and third-level analysis on the data to determine not just individual genes linked to risk, but interactions among different risk factors. He also is collaborating with Tanzi to share data and learn from one another’s findings.

“We are delighted to collaborate with Rotary as we tackle one of the most difficult conundrums relating to the disease,” said Morby. “Understanding the difference in response of women and men to the disease has been a subject that researchers have been reluctant to take on because of its complexity. Cure Alzheimer’s Fund is proud to take on this challenge with the support of an international service organization like Rotary.”

Oct 4, 2016

A Early Intervention for Alzheimer's?

What do the developing brain and the Alzheimer’s brain have in common? Beth Stevens, Ph.D., a developmental neurologist, is investigating an important connection: the loss of synapses, where neurons connect with one another to transmit important signals.

Stevens heads a lab in the F.M. Kirby Neurobiology Center at Children’s Hospital in Boston. She’s a superstar in the field, having received a Presidential Early Career Award for Scientists and Engineers in 2012 and a MacArthur “Genius Award” Foundation Fellowship in 2015. Now, she’s making waves in the Alzheimer’s field. This past May, her lab published a groundbreaking study identifying a pathway that may be responsible for synapse loss in the Alzheimer’s brain, which is closely correlated with cognitive decline.

Synapse loss in development

In the developing brain—from birth to early adolescence—synapse loss occurs normally and frequently. “It’s a ‘use it or lose it’ system,” Stevens explains. “The brain figures out which connections are important and which ones aren’t, based on experience. It prunes the ones it doesn’t need so that it can strengthen the more useful connections.” Synapses allow neurons to communicate with one another, transmitting signals around the brain, enabling us to form thoughts, recall memories, perform motor skills and more. As our brains are molded by synapse growth and loss, our personality and identity also take shape.

Stevens, along with Cure Alzheimer’s Fund Research Consortium member Ben Barres, M.D., Ph.D., published a 2007 paper showing that a protein named “complement” mediates healthy synapse loss. Complement “tags” unnecessary synapses for destruction. In much the same way macrophages devour invading pathogens like bacteria throughout the body, brain cells called microglia devour the complement-marked synapses. This tag-and-destroy activity so important to healthy brain development is also part of the brain’s innate immune system, a first line of defense against infection and disease.

In healthy adults, this complement-pruning pathway largely is turned off. While microglia and complement still play other important roles, they’re no longer trimming synapses on a large scale.

Connections to Alzheimer’s

Stevens first suspected a link between this complement pathway and Alzheimer’s after hearing a lecture by Dennis Selkoe, M.D. Selkoe, a Harvard neurologist previously funded by Cure Alzheimer’s Fund, discussed his finding that synapse loss occurs in Alzheimer’s disease (AD) even before amyloid plaques are detectible. Stevens wondered whether complement might play a role in this very early synapse loss. Collaborating with Soyon Hong, Ph.D., a former graduate student in Selkoe’s lab and now a postdoc in Stevens’ own lab, Stevens launched an investigation to find out whether complement was present in the brains of Alzheimer’s mice.

Their findings supported the hypothesis: complement was upregulated in vulnerable brain regions like the hippocampus in the mice, coating synapses that had been pruned by microglia. Even more intriguing, Stevens and her colleagues found that by disabling or blocking the creation of complement, they could preserve synapses. These protected mice experienced less synapse loss.

 

Cure Alzheimer’s Fund

The next step was to see whether these findings would translate into human brains. Eager to find funding to continue the experiment, Stevens reached out to fellow researcher Rudy Tanzi, Ph.D., of Harvard Medical School/Massachusetts General Hospital, the chairman of the Cure Alzheimer’s Fund Research Consortium. “We were unlikely to get funding from the National Institutes of Health (NIH) to do this work at this early stage,” Stevens says. “It’s brand new research, still high-risk and high-reward. We need more pilot data to prove how promising it is.” At Tanzi’s recommendation, she submitted a proposal to Cure Alzheimer’s Fund,
which awarded a grant to take the
project to its next stage.

Now, Stevens’ lab is looking at tissue and cerebrospinal fluid samples from human patients with mild cognitive impairment (a diagnosis that often precedes Alzheimer’s) and early AD. They’re hoping to see evidence of the same abnormal levels of complement they witnessed in mice. If they do, they then will explore how to prevent the overproduction of complement in humans—and hopefully prevent cognitive decline.

What’s next

“Complement shows real potential as a therapeutic target,” Stevens explains. “It’s especially exciting because it’s involved at a very early point in the disease. If we could stop synapse loss early, we might be able to stop cognitive decline, or at least stave it off for several years.” Stevens is collaborating with fellow Cure Alzheimer’s-funded researcher Cynthia Lemere, Ph.D., to show that protecting synapses also protects against memory loss in mice. There are some challenges ahead, however. Since complement plays other important roles in the brain, a safe and effective therapy would need to regulate it without removing it completely. Stevens also anticipates hurdles with getting a therapy into the brain and making sure it acts specifically, targeting complement alone and no other proteins. “I don’t expect this work will overturn our basic disease model of amyloid, tau and inflammation,” Stevens says, “but it adds another layer.”

Tanzi is excited about the project. “This is a great example of what can happen when scientists from different disciplines collaborate with one another,” he says.

“This is groundbreaking work—exactly the kind of project Cure Alzheimer’s Fund is designed to support,” says Tim Armour, president and CEO of Cure Alzheimer’s Fund. “We’re helping Dr. Stevens to investigate a new idea that both enhances our understanding of Alzheimer’s and opens the door to new therapies. We’re eager to see where her work goes next.”­­­

Jul 7, 2016

Air Pollution and Alzheimer's - Sound the Alarm

New evidence—funded by Cure Alzheimer’s Fund (CAF) and others—has emerged suggesting a strong connection between air pollution and Alzheimer’s disease. “These findings underscore the complexity of this disease,” says CAF President and CEO Tim Armour, “and emphasize the need for a comprehensive approach to stop it.” 

While Alzheimer’s researchers have theorized for a more than a generation that environment and lifestyle play a significant role in the development of Alzheimer’s, only now are they learning about pollution’s important role. “In the last five years,” said University of Southern California gerontologist Caleb Finch, Ph.D., “it’s become very clear to me and others that air pollution is a likely risk factor in Alzheimer’s, as well as in other changes in brain aging that slow our cognitive processes. This is a very large issue that we face globally.”

Thankfully, it’s also an issue researchers are beginning to address seriously. “There are now more than ten labs working on this around the world,” says Finch. “Five years ago, there were just a few. The topic is catching up to the recognition that it merits.” 

Finch is helping to lead the way. A widely acclaimed biomedical gerontologist who specializes in environmental effects on brain aging, he has received numerous scientific awards and has authored 500 research studies, as well as several major books on aging. In 1984, Finch was the founding director of the University of Southern California’s Alzheimer Disease Research Center, funded by the National Institute on Aging. He joined Cure Alzheimer’s Fund’s Scientific Advisory Board in 2014.

Finch’s recent attention to pollution was stimulated by emerging epidemiological studies from USC and elsewhere showing the following:

  • A strong association between urban pollution and shorter life expectancy: about 1.5 years shorter in the U.S. and five years shorter in China. 
  • A direct correlation between urban pollution and a dangerous thickening of
    the walls of the carotid artery, limiting blood flow to the brain. 
  • A strong connection between air pollution and inflammation in parts of the brain affected by Alzheimer’s disease.
  • A direct correlation between urban pollution and decreases in verbal learning, logical reasoning and memory, and executive function in middle-aged and older adults, both in the Los Angeles area and across the U.S. 

 

From all of this, Finch concludes, “It looks to me that air pollution contributes to at least five percent of Alzheimer’s, and it may be much more.”

His own research on pollution’s effect on aging has been spurred in two ways by a 2014 CAF research grant to examine the effect of nano-sized particulate matter (derived mostly from automobile traffic in urban environments) on the creation of Abeta in mice. Small particle air pollution is particularly worrisome, because that is the material that finds its way into the bloodstream. “We’re not worried about the particles larger than 2.5 microns, such as fireplace smoke,” Finch explains. “Those are trapped in the upper airways. The ones that we’re really concerned about are invisible to the human eye — smaller than 2.5 microns. They penetrate deeply into the lung, and they reach the brain.”

That 2014 CAF-funded project, says Finch, developed in conjunction with his USC associate Mafalda Cacciottolo, later led to a substantial grant from the National Institutes of Health. Together, their research established strong evidence that urban pollution is contributing to a toxic increase in Abeta, which in turn leads to the development of Alzheimer’s. 

“This sort of leveraging of small, privately funded projects into much larger, public-funded research is central to the Cure Alzheimer’s Fund mission,” says Armour. 

While the news about air pollution’s neurotoxicity is stunning and worrisome, there is some reassuring news. These  nanoparticles though abundant around the world, are on the decline in some nations. The U.S., for example, has seen a 35 percent decrease in the concentration of small airborne particles from 2000 to 2014. “Fifteen years ago, the bulk of the country was over the EPA safety standard,” Finch says. “Now, more than half of the country is under the safety standard. So we’re making progress.”

“This is a key piece of the puzzle,” says CAF Research Consortium Chair Rudy Tanzi, Ph.D. “Alzheimer’s emerges more than a decade before symptoms begin, with the over-accumulation of Abeta in the brain. As we aggressively move toward therapies to control that process, we need to expand our understanding of the contributing factors.”

 
   

donate now:

An anonymous donor will match all new monthly recurring donations, but only if 75% of donors upgrade to a recurring donation today.
Terms and conditions apply.
Make a monthly recurring donation on your credit card. You can cancel at any time.
Make a donation in honor or memory of:
What kind of card would you like to send?
How much would you like to donate?
  • $10
    (USD)
    give
  • $25
    (USD)
    give
  • $50
    (USD)
    give
  • $125
    (USD)
    give
  • $350
    (USD)
    give
  • $500
    (USD)
    give
  • $1,000
    (USD)
    give
  • $10
    each month

    (USD)
    give
  • $25
    each month

    (USD)
    give
  • $50
    each month

    (USD)
    give
  • $125
    each month

    (USD)
    give
  • $350
    each month

    (USD)
    give
  • $500
    each month

    (USD)
    give
  • $1,000
    each month

    (USD)
    give
  • $
    give
gift Make this donation a gift, in honor of, or in memory of someone?

Reviews of Cure Alzheimer's Fund

Great Nonprofits
Read and write reviews about Cure Alzheimer's Fund on GreatNonProfits.org.
WARNING: Javascript is currently disabled or is not available in your browser. GlobalGiving makes extensive use of Javascript and will not function properly with Javascript disabled. Please enable Javascript and refresh this page.